SCHEMBL334986

SCHEMBL334986

CCN(CC)c1ccc(C(=O)NC(c2ccccc2)C(O)C(=O)Nc2ccc3ccnc(N)c3c2)cc1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 1/20 0.44
F10 P00742 6/20 0.43
CNR2 P34972 1/20 0.42
F9 P00740 1/20 0.41
HTR2C P28335 1/20 0.40
HTR2B P41595 1/20 0.40
ESRRG P62508 1/20 0.40
AURKA O14965 1/20 0.39
RPS6KB1 P23443 1/20 0.39
AURKB Q96GD4 1/20 0.39
HCRTR1 O43613 1/20 0.39
CACNA1B Q00975 1/20 0.39
APBA1 Q02410 1/20 0.39
SMN1; SMN2 Q16637 1/20 0.39
F7 P08709 2/20 0.39
F3 P13726 2/20 0.39
MEN1 O00255 2/20 0.39
NPC1 O15118 2/20 0.39
KMT2A Q03164 2/20 0.39
GBA1 P04062 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL335293 0.93 F9 (0.48) MAPTF10CNR2F9HTR2C
SCHEMBL336042 0.93 F9 (0.48) MAPTF10CNR2F9HTR2C
SCHEMBL335437 0.87 F10 (0.46) MAPTF10F9SMN1; SMN2F7
SCHEMBL335037 0.86 F9 (0.55) F10F9F7F3MEN1
SCHEMBL335988 0.86 F9 (0.44) MAPTF10CNR2F9ESRRG
SCHEMBL335731 0.85 F9 (0.47) MAPTF10F9ESRRGAURKA
SCHEMBL335372 0.85 F9 (0.43) MAPTF10CNR2F9ESRRG
SCHEMBL336900 0.85 F9 (0.47) MAPTF10F9HTR2CHTR2B
SCHEMBL336152 0.84 F9 (0.46) MAPTF10F9ESRRGF7
SCHEMBL335253 0.84 F9 (0.50) MAPTF10F9F7F3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2069289-B1 ISOSERINE DERIVATIVES FOR USE AS COAGULATION FACTOR IXa INHIBITORS SANOFI SA (FR) 2013-10-02 EP claimed
US-8097758-B2 Isoserine derivatives for use as coagulation factor IXa inhibitors SANOFI-AVENTIS (FR) 2012-01-17 US claimed
US-20090233949-A1 ISOSERINE DERIVATIVES FOR USE AS COAGULATION FACTOR IXA INHIBITORS SANOFI-AVENTIS (FR) 2009-09-17 US claimed
CN-101516834-A Isoserine derivatives for use as coagulation factor ixa inhibitors SANOFI AVENTIS (FR) 2009-08-26 CN claimed
CN-1359423-A Herbicide resistant plants HINZENTA CO LTD (GB) 2002-07-17 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090233949-A1 ISOSERINE DERIVATIVES FOR USE AS COAGULATION FACTOR IXA INHIBITORS TFPI, F2, F9 MAPT 3998/4885F10 9/4885CNR2 3688/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.